Suppr超能文献

口腔用氯胺酮治疗抑郁症,1:药理学考虑和临床证据。

Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence.

机构信息

Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India.

出版信息

J Clin Psychiatry. 2019 Apr 2;80(2):19f12820. doi: 10.4088/JCP.19f12820.

Abstract

Clinical evidence is accumulating to support the use of ketamine as a powerful, quick-acting intervention for depression. Ketamine has been administered by oral, sublingual, transmucosal, intravenous, intramuscular, subcutaneous, intranasal, and even rectal routes. Whereas intravenous ketamine is the best studied approach, common sense dictates that oral ketamine is the most practical. The bioavailability of oral ketamine and interindividual variations thereof have been poorly studied; possibly only 20%-25% of an oral dose reaches the bloodstream. This is not necessarily a limitation because, as with other drugs that have poor oral bioavailability, compensation is possible by administering an appropriately higher dose, and interindividual variations can be addressed through individualized dose up-titration. A quarter- century of experience supports the use of oral ketamine for treating acute and chronic pain in children and adults. Case reports, case series, chart reviews, and 3 recent randomized controlled trials (RCTs) show that oral ketamine is effective in treating severe depression, depression with suicidal ideation, and treatment-resistant depression; that oral ketamine, used as an augmentation agent, improves outcomes in patients receiving a conventional antidepressant; and that oral ketamine reduces depression in patients with chronic pain. Doses of oral ketamine have ranged from 0.25 to 7 mg/kg and from 50 mg per occasion to 300 mg per occasion in multiple daily dosing, daily dosing, and intermittent dosing schedules. Oral ketamine was well tolerated in all studies; dropout and reasons for dropout were similar in ketamine and control arms in the 3 RCTs. These findings suggest that if ketamine is to find a place as an off-label treatment for depression and suicidality in mainstream psychiatry, researchers should study the safety, efficacy, and optimization of oral ketamine. Intravenous and intranasal routes may be monetarily more promising, but the oral route could be of greatest service.

摘要

临床证据越来越多,支持使用氯胺酮作为一种有效的、快速起效的抑郁症干预手段。氯胺酮可以通过口服、舌下、黏膜下、静脉、肌肉、皮下、鼻内甚至直肠途径给药。虽然静脉内氯胺酮是研究最多的方法,但常识表明,口服氯胺酮更为实用。口服氯胺酮的生物利用度及其个体间差异研究得很少;可能只有 20%-25%的口服剂量到达血液。这不一定是一个限制,因为与其他口服生物利用度较差的药物一样,可以通过给予适当更高的剂量来补偿,并且可以通过个体化剂量滴定来解决个体间差异。四分之一个世纪的经验支持使用口服氯胺酮治疗儿童和成人的急性和慢性疼痛。病例报告、病例系列、图表回顾和最近的 3 项随机对照试验(RCT)表明,口服氯胺酮在治疗严重抑郁症、有自杀意念的抑郁症和治疗抵抗性抑郁症方面有效;口服氯胺酮作为增效剂,可改善接受常规抗抑郁药治疗的患者的预后;口服氯胺酮可减轻慢性疼痛患者的抑郁症状。口服氯胺酮的剂量范围为 0.25 至 7 毫克/公斤,单次剂量为 50 毫克至 300 毫克,每日多次、每日一次和间歇性给药方案均可。所有研究均表明口服氯胺酮耐受性良好;在 3 项 RCT 中,氯胺酮组和对照组的退出率和退出原因相似。这些发现表明,如果氯胺酮要在主流精神病学中找到作为抗抑郁药和自杀意念的标签外治疗方法的位置,研究人员应该研究口服氯胺酮的安全性、疗效和优化。静脉内和鼻内途径可能在经济上更有前途,但口服途径可能是最有帮助的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验